Silver DE - Search Results

1

Optimizing extended-release carbidopa/levodopa in Parkinson disease: Consensus on conversion from standard therapy.

Espay AJ, Pagan FL, Walter BL, Morgan JC, Elmer LW, Waters CH, Agarwal P, Dhall R, Ondo WG, Klos KJ, Silver DE. Espay AJ, et al. Among authors: silver de. Neurol Clin Pract. 2017 Feb;7(1):86-93. doi: 10.1212/CPJ.0000000000000316. Neurol Clin Pract. 2017. PMID: 28243505 Free PMC article. Review.

2

Long-Term Treatment with Extended-Release Carbidopa-Levodopa (IPX066) in Early and Advanced Parkinson's Disease: A 9-Month Open-Label Extension Trial.

Waters CH, Nausieda P, Dzyak L, Spiegel J, Rudzinska M, Silver DE, Tsurkalenko ES, Kell S, Hsu A, Khanna S, Gupta S. Waters CH, et al. Among authors: silver de. CNS Drugs. 2015 Apr;29(4):341-50. doi: 10.1007/s40263-015-0242-2. CNS Drugs. 2015. PMID: 25895021 Free PMC article. Clinical Trial.

3

Tolerability and efficacy of switching from oral selegiline to Zydis selegiline in patients with Parkinson's disease.

Ondo WG, Hunter C, Isaacson SH, Silver DE, Stewart RM, Tetrud JW, Davidson A. Ondo WG, et al. Among authors: silver de. Parkinsonism Relat Disord. 2011 Feb;17(2):117-8. doi: 10.1016/j.parkreldis.2010.10.001. Epub 2010 Nov 16. Parkinsonism Relat Disord. 2011. PMID: 21084213 Clinical Trial.

4

Physicians' experience with RYTARY (carbidopa and levodopa) extended-release capsules in patients who have Parkinson disease.

Silver DE, Trosch RM. Silver DE, et al. Neurology. 2016 Apr 5;86(14 Suppl 1):S25-35. doi: 10.1212/WNL.0000000000002511. Epub 2016 Apr 4. Neurology. 2016. PMID: 27044647

5

Orally disintegrating selegiline in Parkinson patients with dopamine agonist-related adverse effects.

Lyons KE, Friedman JH, Hermanowicz N, Isaacson SH, Hauser RA, Hersh BP, Silver DE, Tetrud JW, Elmer LW, Parashos SA, Struck LK, Lew MF, Pahwa R. Lyons KE, et al. Among authors: silver de. Clin Neuropharmacol. 2010 Jan-Feb;33(1):5-10. doi: 10.1097/WNF.0b013e3181b7926f. Clin Neuropharmacol. 2010. PMID: 19855267 Clinical Trial.

6

Initiating therapy for Parkinson's disease.

Silver DE, Ruggieri S. Silver DE, et al. Neurology. 1998 Jun;50(6 Suppl 6):S18-22; discussion S44-8. doi: 10.1212/wnl.50.6_suppl_6.s18. Neurology. 1998. PMID: 9633682 Review.

7

Clinical experience with the novel levodopa formulation entacapone + levodopa + carbidopa (Stalevo).

Silver DE. Silver DE. Expert Rev Neurother. 2004 Jul;4(4):589-99. doi: 10.1586/14737175.4.4.589. Expert Rev Neurother. 2004. PMID: 15853578 Review.

8

An open-label evaluation of the tolerability and safety of Stalevo (carbidopa, levodopa and entacapone) in Parkinson's disease patients experiencing wearing-off.

Koller W, Guarnieri M, Hubble J, Rabinowicz AL, Silver D. Koller W, et al. J Neural Transm (Vienna). 2005 Feb;112(2):221-30. doi: 10.1007/s00702-004-0184-1. Epub 2004 Oct 22. J Neural Transm (Vienna). 2005. PMID: 15503197 Clinical Trial.

9

A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease.

Stacy M, Silver D, Mendis T, Sutton J, Mori A, Chaikin P, Sussman NM. Stacy M, et al. Neurology. 2008 Jun 3;70(23):2233-40. doi: 10.1212/01.wnl.0000313834.22171.17. Neurology. 2008. PMID: 18519872 Clinical Trial.

10

Determining the efficacy of rasagiline in reducing bradykinesia among Parkinson's disease patients: a review.

Silver DE, Buck PO. Silver DE, et al. Int J Neurosci. 2011 Sep;121(9):485-9. doi: 10.3109/00207454.2011.582240. Epub 2011 Jun 15. Int J Neurosci. 2011. PMID: 21671840 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

39 results

Search Page

Filters